Noninferiority was observed in neoCARHP: pCR 64% with THP versus 66% with carboplatin-containing therapy, with identical pCR in HR-negative disease and small differences in HR-positive disease.

Female patient talking to doctor. There was no significant difference in event-free survival between the carboplatin-containing arms. Adding carboplatin to neoadjuvant paclitaxel significantly ...

Carboplatin for Premenopausal Triple-Negative Breast Cancer: Time to Rethink the Neoadjuvant Standard? The following represents disclosure information provided by authors of this manuscript. All ...

New findings have provided more evidence that omitting carboplatin from standard neoadjuvant therapy in HER2-positive early breast cancer can improve tolerability without compromising short-term ...

SAN ANTONIO — The addition of carboplatin to a standard neoadjuvant chemotherapy regimen significantly improves disease-free or event-free survival in patients with early-stage triple-negative breast ...

BOSTON -- Some equations used to calculate estimated glomerular filtration rate (eGFR) may alter chemotherapy dosing in cancer patients, a prospective study indicated. Nearly 300 adults beginning ...